Skip to main content
Caplight Logo









Abviris Deutschland GmbH

Abviris Deutschland GmbH

Private
ReinfeldHealthcare & Life Scienceshttps://abviris.com/

Last Round

Series A

Mar 16, 2021

Total Funding Raised

$3.22M

Company Overview

Abviris Deutschland GmbH is a biotechnology company that develops and markets immune-oncology diagnostic tests for the early detection of HPV-induced cancers.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

in-vitro diagnosticsIVDHPV screeninglateral flow immunoassayrapid diagnostic testpoint of care testingPOCTimmuno-oncologycancer screeningblood-based screeningmedical devicechairside diagnosticsbiotechnologyHPV16 detection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abviris Deutschland GmbH Comparables

Compare Abviris Deutschland GmbH with similar companies based on industry and business-model similarity.

Abviris Deutschland GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CURO Biosciences Private Limited
73%
Vigilant Biosciences
73%
Epitype GmbH
67%

Abviris Deutschland GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 16, 2021
SeedJan 21, 2016

Abviris Deutschland GmbH Investors

Notable investors and investment history

Abviris Deutschland GmbH investors
InvestorRounds
MBG Schleswig-HolsteinSeed, Series A
High-Tech GründerfondsSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 16, 2021

    Raised $2M Series A round

  • Jan 21, 2016

    Raised $1M Seed round

Abviris Deutschland GmbH Filings

Explore SEC and related filing metadata, where available.

Abviris Deutschland GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Abviris Deutschland GmbH's valuation, stock price, and market status.

Is Abviris Deutschland GmbH a public or private company?

Abviris Deutschland GmbH is a private company.

What is the current stock price of Abviris Deutschland GmbH?

Abviris Deutschland GmbH is a private company with no public stock price. Caplight tracks Abviris Deutschland GmbH's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Abviris Deutschland GmbH worth (valuation)?

Valuation information for Abviris Deutschland GmbH is not publicly available.

Can I buy Abviris Deutschland GmbH stock?

Abviris Deutschland GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Abviris Deutschland GmbH's last funding round?

Abviris Deutschland GmbH's most recent funding round was Series A on March 16, 2021.

Who are the main investors in Abviris Deutschland GmbH?

Key investors in Abviris Deutschland GmbH include MBG Schleswig-Holstein, High-Tech Gründerfonds.

Will Abviris Deutschland GmbH IPO soon?

No public IPO plans have been announced for Abviris Deutschland GmbH.

How can I track Abviris Deutschland GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Abviris Deutschland GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersReinfeld
Year Founded2014
Last FundingMar 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?